Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

WRHI 060 (ADVANCE): A Randomised, Phase 3 Non-inferiority Study of DTG + TAF + FTC Compared With DTG + TDF + FTC and EFV + TDF + FTC in Patients Infected With HIV-1 Starting First-line Antiretroviral Therapy - Extension to 192 Weeks

Next Previous
Trial Profile

WRHI 060 (ADVANCE): A Randomised, Phase 3 Non-inferiority Study of DTG + TAF + FTC Compared With DTG + TDF + FTC and EFV + TDF + FTC in Patients Infected With HIV-1 Starting First-line Antiretroviral Therapy - Extension to 192 Weeks

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dolutegravir (Primary) ; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate; Emtricitabine/tenofovir alafenamide; Emtricitabine/tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms ADVANCE

Most Recent Events

  • 22 Feb 2023 Results(n=159) assessing changes in weight, lipids, glucose and HBA1C after switch from their original randomized treatment (ADVANCE trial) to TDF/3TC/DTG in the CHARACTERISE trial presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023
  • 15 Dec 2022 Results of a substudy CHARACTERISE (n=172) published in the Clinical Infectious Diseases
  • 26 Oct 2022 Results from DolPHIN-2, ADVANCE, NAMSAL and VISEND, comparing rates of virological failure (VF)and re-suppression in four randomised trials of dolutegravir (DTG), efavirenz (EFV) and protease inhibitors , presented at the 16th International Congress on Drug Therapy and HIV Infection

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top